News
Touchlight's enzymatic dbDNA used as a critical starting material for Versameb's VMB-100, for first-in-human clinical study to treat chronic SUI.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback